Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: One institutional experience in Japan

International Journal of Hematology

Volumn 88, Issue 2, 2008, Pages 159-164

  Nannya, Yasuhito ^a   Yokota, Hiromitsu ^a   Sato, Yumiko ^a   Yamamoto, Go ^a   Asai, Takashi ^a   Ichikawa, Motoshi ^a   Watanabe, Takuro ^a   Kumano, Keiki ^a   Hangaishi, Akira ^a   Takahashi, Tsuyoshi ^a   Chiba, Shigeru ^a   Yatomi, Yutaka ^a   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chronic myelogenous leukemia; Cytogenetic response; Imatinib mesylate; Molecular response

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; HUMAN; HUMAN TISSUE; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; SKIN RUSH; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; JAPAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 56649099154     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0111-6     Document Type: Article

References (15)

1. CL Sawyers 1999 Chronic myeloid leukemia N Engl J Med 340 1330 40
2. RT Silver SH Woolf R Hehlmann 1999 An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology Blood 94 1517 36
3. BJ Druker F Guilhot SG O'Brien 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 17
4. H Kantarjian C Sawyers A Hochhaus 2002 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 645 52
5. Y Morishima M Ogura M Nishimura 2004 Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study Int J Hematol 80 261 6
6. M Emig S Saussele H Wittor 1999 Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR Leukemia 13 1825 32
7. T Hughes M Deininger A Hochhaus 2006 Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 28 37
8. TP Hughes J Kaeda S Branford 2003 Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 1423 32
9. N Tsuji C Kamagata M Furuya 2002 Selection of an internal control gene for quantitation of mRNA in colonic tissues Anticancer Res 22 4173 8
10. BJ Druker M Talpaz DJ Resta 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 7
11. A Horikoshi K Takei S Sawada 2007 Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML) Leuk Res 31 574 5
12. RA Larson BJ Druker F Guilhot 2008 Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood 111 4022 8
13. M Baccarani G Saglio J Goldman 2006 Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 1809 20
14. F Guilhot J Apperley DW Kim 2007 Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase Blood 109 4143 50
15. HM Kantarjian F Giles N Gattermann 2007 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 3540 6